10:39 AM EST - Avant Technologies Inc : Highlights the essential importance of cell encapsulation technology in enabling effective, long-term treatments for type 1 and insulin-dependent type 2 diabetes. By protecting genetically modified cells that produce and secrete insulin, this innovative approach addresses key barriers to cell-based therapies, offering hope for millions of patients worldwide who rely on daily insulin injections. Avant Technologies Inc
shares O.AVAI are trading unchanged at $0.32.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=5512946396463142
